Aclarubicin inhibits etoposide induced apoptosis through inhibition of RNA synthesis in P388 murine leukemic cells

Journal of Experimental and Clinical Cancer Research

Volumn 17, Issue 4, 1998, Pages 435-442

  Nagata, T ^a   Higashigawa, M ^a   Shimono, Y ^a   Cao, D C ^a   Yan Mao, X ^a   M'soka, T ^a   Inamochi, H ^a   Hori, H ^a   Kawasaki, H ^a   Sakurai, M ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aclarubicin (ACR); Antagonistic drug interaction; Apoptosis; DNA double strand breaks; Etoposide (VP 16); RNA synthesis

Indexed keywords

ACLARUBICIN; DEUTERIUM; DNA; ETOPOSIDE; LEUCINE; RNA; URIDINE;

AGAR GEL ELECTROPHORESIS; ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA REPAIR; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG ANTAGONISM; DRUG CYTOTOXICITY; FLOW CYTOMETRY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; RNA SYNTHESIS;

ACLARUBICIN; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; DNA DAMAGE; DNA, NEOPLASM; DRUG INTERACTIONS; ETOPOSIDE; FLOW CYTOMETRY; G1 PHASE; LEUKEMIA P388; MICE; NEOPLASM PROTEINS; NUCLEIC ACID SYNTHESIS INHIBITORS; RNA, NEOPLASM; TUMOR CELLS, CULTURED;

EID: 0032432206     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Jensen P.B., Sfrensen B.S., Demant E.J.F. et al.: Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino) methanesulfon -m-anisidide in human small lung cancer cell lines and on topoisomerase II-mediated DNA cleavage., Cancer Res. 50: 3311-3316. 1990.
2. Holm B., Jensen P.B., Sehested M., Hansen H.H.: In vivo inhibition of etoposide-mediated apoptosis, toxicity, and antitumor effect by the topoisomerase II-uncoupling anthracycline Aclarubicin. Cancer Chemother. Pharmacol. 34: 503-508. 1994.
3. Rowe J.M., Chang A.Y.C., Bennet J.M.: Aclacinomycin A and etoposide (VP-16-213): An effective regimen in previously treated patients with refractory acute myelogenous leukemia. Blood 71: 992-996. 1988.
4. Yoshida T., Nakamura S., Ohtake S. et al.: Salvage chemotherapy of refractory non-Hodgkin's lymphoma with Aclacinomycin, behenoyl ara-C, etoposide, and predonisolone. Cancer Chemother. Pharmacol. 25: 135-138. 1989.
5. Liu L.F.: DNA topoisomerase poisons as antitumor drugs. Annu. Rev.Biochem. 58: 351-375. 1989.
6. Nitiss J.L., Liu Y-X., Harbury P., Jannatipour M., Wasserman R., Wang J.C.: Amsacrine and etoposide hypersensitivity of yeast cells overexpressing DNA topoisomerase II. Cancer Res. 52: 4467-4472. 1992.
7. Jensen P.B., Jensen P.S., Demant E.J.F. et al.: Antagonistic effect of aclarubicine on daunorubicin-induced cytotoxicity in human small cell lung cancer cells : relationship to DNA integrity and topoisomerase II. Cancer Res. 51: 5093-5099. 1991.
8. Oki T., Matsuzawa Y., Yoshimoto A. et al.: New antitumor antibiotics, aclacinomycins A and B. J. Antibiot. (Tokyo) 28: 830-834. 1975.
9. Mosmann T.: Rapid colorimetric assay for cellular growth and survival : application to proliferation and cytotoxicity assays. J. Immunol. Methods 65: 55-63. 1983.
10. Pieters R., Loonen A.H., Huismans D.R. et al.: In vitro drug sensitivity of cells from children with leukemia using the MTT assay with improved culture conditions. Blood 76: 2327-2336. 1990.
11. Higashigawa M., Kuwabara H., Cao D-C. et al.: Heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C cytotoxicity in childhood leukemias which express myeloid markers. Leuk. Lymph. 22, 279-285. 1996.
12. Chou T-C., Talalay P.: Quantitative analysis of dose-effect relationships : the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22: 27-55. 1984.
13. Chou T-C., Talalay P.: Applications of the median-effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents. In: Harrap, K.R., Connors, T. A., eds. New Avenues in Developmental Cancer Chemotherapy, Academic Press: Orlando, FL, 1987: 36-64.
14. Birnboim H.C., Jevcak J.J.: Fluorometric method for rapid detection of DNA strand breaks in human white blood cells produced by low doses of radiation. Cancer Res. 41: 1889-1892. 1981.
15. Tone H., Nishida H., Takeuchi T., Umezawa H.: Experimental studies on aclacinomycin. Drugs Exp. Clin. Res. 11: 9-15. 1985.
16. Sfrensen B.S., Sinding J., Andersen A.H., Alsner J., Jensen P.B., Westergaard O.: Mode of action of topoisomerase II-targeting agents at a specific DNA sequence : uncoupling the DNA binding, cleavable and religation events. J. Mol. Biol. 228: 778-786. 1992.
17. Bertrand R., Kerrigan D., Sarang M., Pommier Y.: Cell death induced by topoisomerase inhibitors : role of calcium in mammalian cells. Biochem. Pharmacol. 42: 77-85. 1991.
18. Ishigami T., Kim K.M., Horiguchi Y. et al.: Anti-IgM antibody-induced cell death in a human B lymphoma cell line, B104, represents a novel programmed cell death. J. Immunol. 148: 360-368. 1992.
19. Chatterjee S., Cheng M.F., Berger N.A.: Hypersensitivity to clinically useful alkylating agents and radiation in poly(ADP-ribose) polymerase-deficient cell lines. Cancer Commun. 2, 401-407. 1990.
20. Clarke A.R., Purdie C.A., Harrison D. J. et al.: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 786-852. 1993.
21. Lane D.P.: A death in the life of p53. Nature 362: 786-787. 1993.
22. O'Connor P.M., Kohn K.W.: A fundamental role for cell cycle regulation in the chemosensitivity of cancer cells? Semin. Cancer Biol. 3, 409-416. 1992.
23. Shi Y., Glynn J.M., Guilbert L.J., Cotter T.G., Bissonnette R.P., Green D.R.: Role for c-myc in activation-induced apoptotic cell death in T-cell hybridomas. Science 257, 212-214. 1992.
24. Kamesaki S., Kamesaki H., Jorgensen T.J., Tanizawa A., Pommier Y., Cossman J.: Bcl-2 protein inhibits etoposide-induced apoptosis through its effects on events subsequent to topoisomerase II-induced DNA strand breaks and their repair. Cancer Res. 53: 4251-4256. 1993.
25. D'Arpa P., Beardmore C., Liu L.F.: Involvement of nucleic acid synthesis in cell killing mechanisms of topoisomerase poisons. Cancer Res. 50: 6919-6924. 1990.
26. Kaufmann S.H.: Antagonism between camptothecin and topoisomerase II-directed chemotherapeutic agents in a human leukemia cell line. Cancer Res 51: 1129-1136. 1991.